$57.38
+0.16 (+0.28%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INSP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 4 observational · 1 with posted results
Held by 10 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., Artisan Partners Limited Partnership, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, +5 more) · FINRA short interest 5.0 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| EURO-STIM RegistryNCT06971796observationalApnea Hypopnea Index (AHI) | — | Recruiting | Device: Inspire UAS System | Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA) | 1,000 | Apr 2035 | ≤ 3,176 d | 2025-09-08 |
| Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval StudyNCT07113288observationalIncidence of Procedure and/or Device Related Adverse Events (Safety and Tolerability) | — | Recruiting | Device: Inspire® UAS System | Obstructive Sleep Apnea (OSA) | 70 | 2032-01-01 | in 1,961 d | 2026-03-27 |
| Pediatric Down Syndrome Post-Approval StudyNCT06851338Safety Outcome Measure - Procedure and Device-related Adverse eventsOpen-label · Treatment | Not applicable | Recruiting | Device: Hypoglossal Nerve Stimulation | Pediatric Obstructive Sleep Apnea, Down Syndrome (DS) | 60 | May 2030 | ≤ 1,381 d | 2025-02-28 |
| Pediatric Post-Approval RegistryNCT04457154observationalEvaluation of device and/or procedure related adverse events over time | — | Recruiting | Device: Inspire Upper Airway Stimulation System | Obstructive Sleep Apnea | 60 | Dec 2027 | ≤ 499 d | 2025-02-25 |
| Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep ApneaNCT04801771Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2)Open-label · Treatment | Phase 3 | Active, not recruiting | Device: Inspire Upper Airway Stimulation (UAS) System | Down Syndrome, Obstructive Sleep Apnea | 57 | 2027-02-28 | in 193 d | 2025-09-18 |
| Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International RegistryNCT02907398observationalChange in Apnea Hypopnea (AHI) from Baseline to 12-Months | — | Unknown status | Device: Inspire therapy · Other: No intervention | Obstructive Sleep Apnea | 5,000 | Sep 2025 | — | 2025-06-19 |
| Inspire Singapore StudyNCT06540716Inspiratory OverlapOpen-label · Treatment | Not applicable | Completed | Device: Inspire System | Obstructive Sleep Apnea, OSA, Sleep Apnea | 44 | 2025-07-17actual | — | 2026-05-22 |
| Inspire® Post-Approval Study / Protocol Number 2014-001NCT02413970Long-term Device-Related SAEsOpen-label · Treatment | Not applicable | Unknown status | Device: Inspire® UAS System | Obstructive Sleep Apnea | 127 | Mar 2025 | — | 2024-12-27 |
| The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep ApneaNCT05428839Measurement of pharyngeal width to determine if there is correlation between pharyngeal width and presence or absence of complete concentric collapse at the soft palate during drug induced sleep endoscopyOpen-label · Diagnostic | Not applicable | Unknown status | Diagnostic test: Pharyngeal width measurement | Sleep Apnea, Obstructive | 300 | 2024-01-11actual | — | 2024-10-17 |
| Inspire Home Study: Utilization of Home Monitoring During Therapy Optimization in Patients With an Inspire Upper Airway Stimulation System (Comparison of Home Sleep Testing vs. In-lab Polysomnography Testing)NCT04416542Comparison of Apnea-Hypopnea Index (AHI), between the two randomization armsRandomized · Open-label · Treatment | Not applicable | Completed | Diagnostic test: Home Sleep Testing | Obstructive Sleep Apnea | 64 | 2022-06-10actual | — | 2022-06-21 |
| Inspire® Upper Airway Stimulation (UAS) System German Post-Market StudyNCT02293746Number of Reported SAEs / Procedure & Device Related AEsOpen-label · Treatment | Phase 4 | Completed | Device: Inspire® Upper Airway Stimulation (UAS) System | Obstructive Sleep Apnea | 60 | 2016-12-11actual | — | 2020-07-02 |
| Inspire® Upper Airway Stimulation SystemNCT02675816Change from Baseline OSA at 3 MonthsOpen-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Study halted due to low recruitment. Reimbursement changes require a larger study with additional centers and therefore, a new study planned as replacement. | Device: Inspire® Upper Airway Stimulation (UAS) System | Obstructive Sleep Apnea | 16 | Jul 2016actual | — | 2016-08-11 |
| Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)NCT01161420results2014-12-15Apnea Hypopnea IndexOpen-label · Treatment | Phase 3 | Completed | Device: Inspire Upper Airway Stimulation System | Obstructive Sleep Apnea | 929 | Mar 2013actual | — | 2017-08-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19